Biocompatible gold nanoparticles designed to absorb light at wavelengths of high tissue
transparency have been of particular interest for biomedical applications. The ability of such …

While patient age and gender are important factors in the clinical decision‐making for
treating urothelial carcinoma of the bladder (UCB), there are no evidence‐based …

Cancers infiltrated with T-cells are associated with a higher likelihood of response to PD-1/PD-L1
blockade. Counterintuitively, a correlation between epithelial–mesenchymal transition (…

… Author links open overlay panel John P. Sfakianos a b , Eugene K. Cha a , Gopa Iyer c d , …
Sfakianos was a research fellow in urologic oncology supported by NIH T32-CA82088. …

Programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1)-blockade
immunotherapies have limited efficacy in the treatment of bladder cancer. Here, we show that …

Purpose Given that randomized trials exploring adjuvant chemotherapy for bladder cancer
have been underpowered and/or terminated prematurely, yielding inconsistent results and …

Purpose We determined whether restaging resection before initiating induction intravesical
bacillus Calmette-Guérin improves the recurrence-free rate in patients with high risk …

Purpose: To investigate genomic differences between urothelial carcinomas of the upper
tract (UTUC) and bladder (UCB), with a focus on defining the clonal relatedness of temporally …

Urothelial carcinoma of the bladder (UCB) is genomically heterogeneous, with frequent
alterations in genes regulating chromatin state, cell cycle control, and receptor kinase signaling. …

Purpose Owing to its exquisite chemotherapy sensitivity, most patients with metastatic germ
cell tumors (GCTs) are cured with cisplatin-based chemotherapy. However, up to 30% of …